ELDN
Eledon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.62
−1.13%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.66
From 52W high−39.91%
Volume827166.00
Market cap$212.90M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$2.66
From 52W high
−39.91%
Volume
827166.00
Market cap
$212.90M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
21.6
MomentumView details →
1D Return
−1.13%
YTD Return
+71.19%
SummaryUpdated Jun 1, 2026
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Irvine, California. Originally known as Novus Therapeutics, Inc., the company underwent a strategic transformation and changed its name to Eledon Pharmaceuticals in January 2021. The company focuses on developing innovative medicines for patients living with autoimmune diseases, amyotrophic lateral sclerosis (ALS), and those requiring organ or cell-based transplants.
Similar companies
Latest newsMore news →
Eledon Pharmaceuticals dosed the first patients under compassionate use of tegoprubart in highly sensitized patients with pre-existing antibodies receiving a kidney transplant.17d agoEledon Pharmaceuticals enrolled the first patients in a new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant.17d agoEledon Pharmaceuticals submitted an Investigational New Drug application to the U.S. FDA for a registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes.17d ago